Immunitybio Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Immunitybio
IBRX Stock  USD 2.81  0.10  3.44%   
Immunitybio financial statements provide useful quarterly and yearly information to potential Immunitybio investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Immunitybio financial statements helps investors assess Immunitybio's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Immunitybio's valuation are summarized below:
Gross Profit
14.7 M
Market Capitalization
2.5 B
Enterprise Value Revenue
191.3059
Revenue
14.7 M
Earnings Share
(0.62)
We have found one hundred twenty available fundamental trends for Immunitybio, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Immunitybio regular market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 2.7 B in 2025. Enterprise Value is likely to drop to about 2.8 B in 2025

Immunitybio Total Revenue

15.48 Million

Check Immunitybio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunitybio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 12.5 M, Interest Expense of 138.2 M or Selling General Administrative of 100.2 M, as well as many indicators such as Price To Sales Ratio of 115, Dividend Yield of 0.0 or Days Sales Outstanding of 55.5. Immunitybio financial statements analysis is a perfect complement when working with Immunitybio Valuation or Volatility modules.
  
Check out the analysis of Immunitybio Correlation against competitors.
For more information on how to buy Immunitybio Stock please use our How to Invest in Immunitybio guide.

Immunitybio Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets299.1 M382.9 M223 M
Slightly volatile
Short and Long Term Debt Total40.2 M42.3 M156.3 M
Slightly volatile
Other Current Liabilities26.2 M33.3 M19.7 M
Slightly volatile
Total Current Liabilities104.2 M54.9 M78.5 M
Slightly volatile
Property Plant And Equipment Net92 M170.5 M68.5 M
Slightly volatile
Current Deferred Revenue85.5 K90 K260.6 K
Slightly volatile
Accounts Payable7.2 M6.7 M5.7 M
Slightly volatile
Cash94.3 M143.4 M70.3 M
Slightly volatile
Non Current Assets Total124.4 M198.3 M92.8 M
Slightly volatile
Cash And Short Term Investments159.8 M149.8 M119 M
Slightly volatile
Net Receivables2.7 M2.4 M2.1 M
Slightly volatile
Common Stock Total Equity50.7 K48.3 K17.9 K
Slightly volatile
Liabilities And Stockholders Equity299.1 M382.9 M223 M
Slightly volatile
Non Current Liabilities Total856.9 M816.1 M231 M
Slightly volatile
Other Current Assets25.4 M24.1 M9.1 M
Slightly volatile
Other Stockholder Equity3 B2.9 B1.1 B
Slightly volatile
Total Liabilities914.6 M871.1 M305.5 M
Slightly volatile
Property Plant And Equipment Gross283.5 M270 M98.2 M
Slightly volatile
Total Current Assets174.7 M184.6 M130.2 M
Slightly volatile
Short Term Debt14.2 M14.9 M49.7 M
Slightly volatile
Intangible Assets16.7 M15.9 M6.5 M
Slightly volatile
Common Stock89.2 K85 K25.9 K
Slightly volatile
Common Stock Shares Outstanding433.3 M700.4 M376.8 M
Slightly volatile
Short Term Investments6.1 M6.4 M82 M
Slightly volatile
Other Assets4.4 M7.6 M3 M
Slightly volatile
Capital Surpluse1.3 B2.2 B1.1 B
Slightly volatile
Property Plant Equipment173.5 M165.2 M63 M
Slightly volatile
Other Liabilities26.6 M25.3 M11.2 M
Slightly volatile
Long Term Debt428 M461.9 M307.3 M
Slightly volatile
Capital Lease Obligations43.9 M42.3 M28.4 M
Slightly volatile
Capital Stock59.8 K85 K44.5 K
Slightly volatile
Non Current Liabilities Other190.3 M285 M72.1 M
Slightly volatile
Deferred Long Term Liabilities129.6 K145.8 K159 K
Slightly volatile
Short and Long Term Debt402.1 M496.7 M334.6 M
Slightly volatile
Inventory13.9 M7.4 M23.3 M
Slightly volatile

Immunitybio Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization12.5 M17.6 M8.6 M
Slightly volatile
Selling General Administrative100.2 M168.8 M70 M
Slightly volatile
Total Revenue15.5 M14.7 M2.4 M
Slightly volatile
Other Operating Expenses234.1 M358.9 M162.5 M
Slightly volatile
Research Development125.8 M190.1 M86.9 M
Slightly volatile
Total Operating Expenses234 M358.9 M162.4 M
Slightly volatile
Interest Income1.9 M2.4 M3.4 M
Slightly volatile
Selling And Marketing Expenses22.7 M25.6 M27.9 M
Slightly volatile
Reconciled Depreciation17.6 M17.6 M15 M
Slightly volatile
Non Recurring544.8 K612.9 K668.2 K
Slightly volatile

Immunitybio Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation35.6 M34.4 M35.7 M
Pretty Stable
Begin Period Cash Flow279.1 M265.8 M81.6 M
Slightly volatile
Depreciation23.7 M22.6 M9 M
Slightly volatile
Capital Expenditures6.5 M6.9 M15 M
Slightly volatile
End Period Cash Flow100 M143.9 M74.5 M
Slightly volatile
Net Borrowings145.1 M200.2 M91.6 M
Slightly volatile
Dividends Paid673 K708.4 K22.8 M
Pretty Stable
Issuance Of Capital Stock112.5 M111.4 M62.3 M
Slightly volatile
Cash Flows Other Operating2 M3.3 M1.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1151214.2 K
Very volatile
Days Sales Outstanding55.558.41987.8 K
Very volatile
Stock Based Compensation To Revenue2.222.3352514
Slightly volatile
Capex To Depreciation0.290.3051.6742
Very volatile
EV To Sales1081144.4 K
Very volatile
Inventory Turnover0.740.830.9013
Slightly volatile
Days Of Inventory On Hand318358390
Slightly volatile
Sales General And Administrative To Revenue802544588
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue12.2512.8955288
Pretty Stable
Capex To Revenue0.440.4671107
Pretty Stable
Cash Per Share0.20.21480.8386
Pretty Stable
Income Quality0.510.94580.572
Slightly volatile
Intangibles To Total Assets0.06990.04160.129
Slightly volatile
Current Ratio3.193.35957.4411
Pretty Stable
Receivables Turnover6.566.24792.0465
Slightly volatile
Capex Per Share0.00940.00990.0722
Pretty Stable
Revenue Per Share0.02010.02110.1919
Slightly volatile
Interest Debt Per Share0.240.24951.1323
Slightly volatile
Debt To Assets0.10.11040.6141
Pretty Stable
Operating Cycle55.558.41987.8 K
Very volatile
Ebt Per Ebit0.871.20161.0317
Slightly volatile
Quick Ratio3.053.2097.4197
Pretty Stable
Net Income Per E B T1.11.151.0141
Slightly volatile
Cash Ratio2.482.61044.2545
Pretty Stable
Days Of Inventory Outstanding318358390
Slightly volatile
Days Of Sales Outstanding55.558.41987.8 K
Very volatile
Free Cash Flow Operating Cash Flow Ratio1.261.01761.1293
Pretty Stable
Fixed Asset Turnover0.08220.086511.7446
Slightly volatile
Debt Ratio0.10.11040.6141
Pretty Stable
Price Sales Ratio1151214.2 K
Very volatile
Asset Turnover0.03280.03850.0779
Slightly volatile

Immunitybio Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.7 B2.9 B2 B
Pretty Stable
Enterprise Value2.8 B3.5 B2.2 B
Pretty Stable

Immunitybio Fundamental Market Drivers

Cash And Short Term Investments149.8 M

Immunitybio Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Immunitybio Financial Statements

Immunitybio investors use historical fundamental indicators, such as Immunitybio's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immunitybio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue90 K85.5 K
Total Revenue14.7 M15.5 M
Stock Based Compensation To Revenue 2.34  2.22 
Sales General And Administrative To Revenue 543.71  802.07 
Research And Ddevelopement To Revenue 12.90  12.25 
Capex To Revenue 0.47  0.44 
Revenue Per Share 0.02  0.02 
Ebit Per Revenue(23.34)(24.51)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Immunitybio Stock Analysis

When running Immunitybio's price analysis, check to measure Immunitybio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunitybio is operating at the current time. Most of Immunitybio's value examination focuses on studying past and present price action to predict the probability of Immunitybio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunitybio's price. Additionally, you may evaluate how the addition of Immunitybio to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY